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Abstract
Objectives
UK Biobank is a UK-wide cohort of 502,655 people aged 40–69, recruited fromNational
Health Service registrants between 2006–10, with healthcare data linkage. Type 2 diabetes
is a key exposure and outcome.We developed algorithms to define prevalent and incident
diabetes for UK Biobank. The algorithmswill be implemented by UK Biobank and their
results made available to researchers on request.
Methods
We used UK Biobank self-reportedmedical history and medication to assign prevalent dia-
betes and type, and tested this against linked primaryand secondary care data in Welsh UK
Biobank participants.Additionally, we derived and tested algorithms for incident diabetes
using linked primaryand secondary care data in the English Clinical Practice Research
Datalink, and ran these on secondary care data in UK Biobank.
Results and Significance
For prevalent diabetes, 0.001% and 0.002% of people classified as “diabetes unlikely” in
UK Biobank had evidence of diabetes in their primaryor secondary care record respec-
tively. Of those classified as “probable” type 2 diabetes, 75% and 96% had specific type 2
diabetes codes in their primaryand secondary care records. For incidence, 95% of people
with the type 2 diabetes-specific C10F Read code in primarycare had corroborative evi-
dence of diabetes frommedications, blood testing or diabetes specific process of care
codes. Only 41% of people identified with type 2 diabetes in primarycare had secondary
care evidence of type 2 diabetes. In contrast, of incident cases using ICD-10 type 2 diabetes
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specific codes in secondary care, 77% had corroborative evidence of diabetes in primary
care. We suggest our definition of prevalent diabetes fromUK Biobank baseline data has
external validity, and recommend that specific primarycare Read codes should be used for
incident diabetes to ensure precision. Secondary care data should be used for incident dia-
betes with caution, as around half of all cases are missed, and a quarter have no corrobora-
tive evidence of diabetes in primarycare.
Introduction
UK Biobank (UKB) is a prospective cohort comprising half a million participants recruited
from the general population aged 40–69 years, with genotypic, phenotypic and linked health
care record data. It was designed to improve prevention, diagnosis and treatment of diseases of
middle and old age[1]. Diabetes is one of the most prevalent conditions in the UKB population,
with around twenty-five thousand cases self-reported at baseline[2], and is forecast to be the
most common disease outcome, with an estimated 25,000 incident cases by 2017, and 40,000
by 2022[3]. Thus, diabetes forms a key exposure, effectmodifier and outcome in UKB; its accu-
rate ascertainment and sub-classification is a priority in ensuring the usefulness of UKB data to
the research community. The UKB Diabetes Outcomes Adjudication Group was convened to
provide guidance in defining prevalent and incident diabetes diagnoses within UKB, using
questionnaire, linked primary and secondary care data.
There is no single agreed gold standard for establishing prevalent diabetes in observational
studies. Validity of diabetes self-report in epidemiological studies varies considerably, with pos-
itive predictive values ranging between 67–92%[4–6]. Discrepancies are also observedwhen
self-completed versus interviewer-deliveredquestionnaire are compared, with a reported 74%
concordance between these two methods[7]. UK studies examining the accuracy of diabetes
diagnosis in primary care records have consistently identified incorrectly diagnosed diabetes,
misclassification of diabetes type, and use of ambiguous Read codes (5–17%, 10–26% and
9–15% respectively)[8,9]. Reliance on secondary care data alone will miss a significant propor-
tion of type 2 diabetes cases, as it is largely managed in primary care.
We aimed to develop algorithms to establish prevalent and incident diabetes diagnoses in
UK Biobank, using self-report and primary and secondary care data. Additionally, we offer
guidance on their usage for researchers. Algorithms will be implemented by UKB and their
results made available to researchers on request.
Methods
Three data sources were used in these analyses (Fig 1).
Firstly, baseline data and linked hospital admissions records dating from 1997 to 2012 (with
complete data to 2010) were requested from the UK Biobank (UKB) data repository
(n = 502,665). UKB participants were recruited fromNHS registers and assessed at 22 centres
between 2006–2010 across the UK[3]. Approximately 9 million invitation letters were sent to
yield half a million participants, a response rate of 5.5%[10]. Baseline assessment included a
health and lifestyle questionnaire (both self-completed by computer touchscreen and research
nurse interview)[10].
Secondly, we used a subset of UKB participants living inWales (comprising around half of
theWelsh UKB population, n = 12,228), for whom linked primary and secondary care data
Recommendations for Diabetes Definition in UK Biobank
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were available via theWelsh SecureAnonymised Information Linkage databank (SAIL)[11]
and the Patient Episode Database for Wales (PEDW) respectively.
Thirdly, we used a cohort of participants from the Clinical Practice Research Datalink
(CPRD, n = 1,048,972). As linked primary and secondary care data were available for only half
of Welsh UKB participants (capturing ~ 2% of all UKB participants),CPRD, a separate English
dataset, was used to compare completeness of incident diabetes ascertainment using primary
and secondary care data sources. CPRD contains anonymised primary care data for over 5 mil-
lion patients from 650 general practices in England andWales, with linked secondary care data
Fig 1. Data sources used in the developmentof UK Biobankdiabetesprevalence and incidencealgorithms.Solid arrows indicate established
linkages, dotted arrows indicate anticipated linkages. 1data used to derive prevalence algorithms, 2data used to test prevalence algorithms, 3data used to
derive incidence algorithms, 4data used to test incidence algorithms. HES = Hospital episode statistics, SMR01 = Scottishmorbidity record, SAIL = Secure
anonymised information linkage databank, PEDW = patient episode database for Wales, CPRD = clinical practice research datalink.
doi:10.1371/journal.pone.0162388.g001
Recommendations for Diabetes Definition in UK Biobank
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fromHospital episode statistics (HES) for around 50%[12]. For bothWelsh UKB and CPRD
participants, primary care data are held in Read code format[13] and secondary care data in
International Classification of Diseases (ICD) code format. While CPRD has the advantage of
size, it is not linked to UKB (Fig 1).
Secondary care in-patient admission data linkage for England (HES), Scotland (ScottishMor-
bidity Record [SMR01]) andWales (Patient Episode Database forWales [PEDW]) is established
in UKB. Linkage with English and Scottish primary care data is anticipated in the future, and it is
envisaged this will be the chief source of incident diabetes diagnoses (Fig 1). The main source of
information for prevalent diabetes at UKB inception is the baseline assessment. For incident
cases occurringafter recruitment, we have designed algorithms to interrogate primary and sec-
ondary care data, recognising that at least initially, researchers will have to rely on secondary care
data alone, since primary care data linked to UKB are not yet available for the whole cohort.
A governing principle for UKB disease categorisation algorithms, given the focus on genetic
analysis, is to ensure that cases are truly cases, whereas false negatives can be tolerated. Given
the size of the dataset, this should only result in minimal contamination of controls.
UKB acquired ethics approval from the North West Multi-Centre Research Ethics Commit-
tee (06/MRE08/65). All investigations were conducted according to the principles in the Decla-
ration of Helsinki. Written informed consent for data collection and record linkage was
obtained from all UKB participants.
Prevalence algorithms
Derivation. We designed algorithms for UKB baseline assessment data to assign presence
and type of diabetes. This was achieved by combining clinical knowledgewithmultiple cross-tabu-
lations of available data (comprising diagnosis, age at diagnosis, diabetes type, diabetesmedications
and diabetes complications). By examining patterns of congruent or contradictory evidence for
diagnoses,we created logical rules capable of assigning or ruling out various diabetes-related end-
ing states (S1 Appendix). The algorithms consisted of three stages: algorithm 1 assigned an overall
likely diabetes status, algorithm 2 finalised type 1 diabetes diagnoses and algorithm 3 finalised type
2 diabetes diagnoses.As no algorithm can be definitive, we assigned a status of “probable” diabetes
where there was greater certainty, and “possible" diabetes where there was less certainty.
Testing.
a). UKB baseline self-reportdata: The algorithm was run on the baseline UKB dataset
and final diabetes status recorded.
b). UKB baseline self-reportdata vs. primary care data in the linkedWelsh UKB sub-
cohort: Primary care data linked to UKB were available for a proportion of the
Welsh participants.We ran the algorithm on this linked dataset. We then examined
pertinent primary care data (diabetes-specificC10 diagnostic codes, diabetesmedica-
tion, hyperglycaemia on blood testing and diabetes process of care codes e.g. for foot
screening) against UKB final diabetes status to assess likely validity.
c). UKB baseline self-reportdata vs. secondarycare data in UKB: Lastly, we compared
final categorisations with prevalent diabetes diagnoses from secondary care data (HES)
linked to UKB, i.e. those where the date of the first diabetes ICD-10 code (E10, E11,
E13 or E14) in hospital admissions date preceded the UKB baseline assessment date.
Implementation. Prevalence algorithms were implemented in the UKB cohort at baseline
to give a single estimation of prevalent diabetes status for all UKB participants.
Recommendations for Diabetes Definition in UK Biobank
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Incidence algorithms
Derivation. We designed algorithms for application to primary and secondary care data
to establish incident diabetes cases. Our focus was on type 2 diabetes, given the age of UKB par-
ticipants at recruitment. To assist generalisability to the UKB population, we restricted CPRD
data to those on whomwe had linked secondary care data, people aged 40–69 years on 1st Janu-
ary 2006, (to reflect age entry criteria for UKB) Primary care algorithms were derived based on
four types of evidence: 1) Diabetes diagnostic codes (considered separately as any diagnostic
code and the more specific C10E [type 1 diabetes] or C10F [type 2 diabetes] codes, these are a
requirement for the Quality Outcomes Framework [QOF] system[14]), 2) Diabetes medica-
tion, (excluding those on metformin only as this has other prescribing indications e.g. pre-dia-
betes, polycystic ovarian syndrome and is therefore not wholly diabetes specific), 3)
Hyperglycaemia on blood results (defined as HbA1c6.5% or 48 mmol/mol, or fasting/ ran-
dom/ unspecified glucose11.1mmol/l) and 4) Presence of diabetes process of care codes
(restricted to those routinely recorded for QOFmonitoring purposes, e.g. retinopathy screen-
ing, foot checks etc.). The threshold for glucose was chosen because primary care records fre-
quently do not specify whether glucose is fasting or not, and we wished to avoid false positives
from a non-fasting glucose in the 7.0–11.1 mmol/l range. Using CPRD and the linkedWelsh
UKB sub-cohort, we used an iterative approach, cross-tabulating evidence at each step, to
determine the logical steps to include in the algorithm and in what order. We then applied the
final incidence algorithm to both databases. For CPRD, we excluded prevalent diabetes accord-
ing to pre-existing C10 diabetes-specificRead codes, and for theWelsh dataset, we removed all
those with prevalent diabetes according to our UKB algorithm.
When developing the incidence algorithms intended for secondary care data, we defined
incident diabetes type based on ICD-10 codes (E10 = type 1 diabetes, E11 = type 2 diabetes,
E13/E14 = unspecifieddiabetes). Prevalent diabetes was excluded as above.
For both primary and secondary care incidence algorithms, we derived event dates by taking
the mid-point between the last primary care consultation/ hospital admission without diabetes
and the date of the first diabetes Read code/ ICD code/ diabetes medication/ hyperglycaemic
blood test/ fifth process of care code. If there were no previous consultations or admissions, we
used the UK Biobank inception date. The date of the first diabetes Read code/ ICD code/ diabe-
tes medication/ hyperglycaemic blood test/ fifth process of care code will be available to
researchers separately if they wish to calculate the event date in an alternative manner.
Testing.
a). Choosing the most appropriate primary care codes in CPRD:We compared the
use of Read codes alone to establish incident diabetes in primary care with the com-
bination of diabetes related measures (medication, hyperglycaemia and process of
care codes).We performed a sensitivity analysis to establish whether we were miss-
ing many incident cases by excluding people in receipt of metformin alone with no
other evidence of diabetes.
b). Choosing the most appropriate number of secondarycare codes in HES-linked
CPRD: Following a secondary care admission, a maximum of 20 distinct diagnostic
codes can be recorded.We compared restriction of secondary care incident diabetes
to the first two positions, versus mention in any position, with presence of diabetes
Read codes (i.e. C10) in primary care.
c). Primary vs. secondarycare data in CPRD: For individuals assigned incident diabe-
tes status from primary care data, we compared sociodemographic characteristics,
diabetes medication, blood tests, diabetes complications, cardiovascular disease
Recommendations for Diabetes Definition in UK Biobank
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(CVD) risk factors and co-morbidities in those with and without corroborating inci-
dent diagnoses in secondary care data. We also compared these characteristics in
those for whom we only had a secondary care diagnosis of diabetes.
d). Secondarycare data in UKB:Using our prevalence algorithm, we excluded partici-
pants with prevalent diabetes at baseline (classed as either “probable type 1 diabetes”
or “probable type 2 diabetes”), then ran the secondary care data incidence algorithm
in the UKB dataset and recorded final status.
Implementation. Incidence algorithms will be applied to the UKB cohort on a yearly
basis, once the necessary linkages with primary care data have beenmade.
Results
All 502,665 UKB participants were included, with a mean age of 57 years at baseline (2006–
2010). Just over half (54%) were female and 95% of white European origin (Table 1).
There were 12,228Welsh UKB participants with linked primary and secondary care data. In
CPRD, records from 1,101,101 individuals who matched the age range at UKB recruitment
and had linked primary and secondary care records were available. UKB participants’ smoking
rates were much lower than CPRD participants’, suggesting the former are a healthier popula-
tion. Around 5% of UKB individuals reported some form of diabetes, 4% reported receipt of
anti-diabeticmedication but only 0.3% reportedmicrovascular diabetic complications
(Table 2).
Prevalence algorithms
Testing.
a). UKB baseline self-reportdata:After application of the algorithm, 95% (476,191/
502,665) of UKB participants were deemed unlikely to have diabetes (Fig 2A–2D).
Proportions for “probable/ possible” prevalent type 1 diabetes and “probable/ possible” preva-
lent type 2 diabetes were 0.4% and 4.7% respectively. Similar proportions were found when the
self-report algorithmwas run on theWelsh UKB linked sub-cohort, though numbers in each
category were relatively small (Table 3).
Table 1. Baseline characteristics of UK Biobank (all),Welsh UK Biobank participants (withUK Biobank, primary and secondarycare data linkage),
and CPRD (primaryand secondarycare data linkage).
UKB cohort LinkedWelsh UKB sub-cohort CPRD
N 502, 665 12,228 1,101,101
Female,% 273,468 (54) 6,580 (54) 544,585 (50)
Mean age, years 57±8 53 ±8.2 53±8.5
Ever smoked, % 168,307 (34) 4,938 (44) 573,301 (52)
Ethnic group, %
European 472,831 (95) - 727,758 (66)
South Asian 8,067(2) - 17,228 (2)
AfricanCaribbean 8,066 (2) - 10,645 (1)
Other 10,907 (2) - 11,653 (1)
Unknown - 333,817 (30)
doi:10.1371/journal.pone.0162388.t001
Recommendations for Diabetes Definition in UK Biobank
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b). UKB baseline self-reportdata vs. primary care data in the linkedWelsh UKB sub-
cohort:Of the UKBWelsh primary care linked participants assigned "diabetes
unlikely" status, only 0.001% (10/11,560) had evidence of diabetes in their primary
care data (Table 3). Of those assigned "probable” type 1 diabetes status, 61% (22/36)
had a definite C10E (type 1 specific) diagnostic code and 56% were on insulin exclu-
sively (20/36). The median age at diagnosis in the probable type 1 diabetes group was
30 years. In contrast, of the 9 individuals assigned “possible” type 1 diabetes, 22%
(2/9) had a C10E code in primary care, and only 11% (1/9) were on insulin only.
Median age at diagnosis for this group was 40 years. Of those assigned "probable”
type 2 diabetes status according to the UKB algorithms, 74% (378/513) had a C10F
(type 2 specific) diagnostic code and an older median age at diagnosis (56 years).
Only one participant was on insulin alone. With the less certain classification of
“possible” type 2 diabetes, 63% (55/87) had a C10F code. Age at diagnosis was youn-
ger (50 years), and a greater proportion were on insulin (alone or in combination)
than those classified as “probable” type 2 diabetes (71% versus 10%).
Table 2. Diabetes-relatedbaseline self-reportvariables available in UKBiobank, N = 502,665.
Touchscreen self-report data
Diagnoses Diabetes diagnosed by doctor 26,408 (5.3)
Gestational diabetes only 1,072 (0.4)
Diabetes diagnosed by doctor (excluding gestational only) 25,336 (5.1)
Age diabetes diagnosed, years 54 (46–60)
Medication On insulin 5,613 (1.1)
Started insulin within one year diagnosis of diabetes 3,034 (0.6)
Nurse verbal interview
Diagnoses Non-specified diabetes 21,738 (4.3)
Age at non-specified diabetes diagnosis, years 55(47–61)
Gestational diabetes 285 (0.10)
Age at gestational diabetes diagnosis, years 37 (30–44)
Type 1 diabetes 428 (0.09)
Age at type 1 diabetes diagnosis, years 30 (20–43)
Type 2 diabetes 3,367 (0.67)
Age at type 2 diabetes diagnosis, years 56 (49–61)
Medications Insulin 5,317 (20.0)
Metformin 14,657 (55.5)
Sulphonylureas 5,596 (21.1)
Meglitinides 135 (0.51)
Glitazones 1,997 (7.6)
Any non-metformin oral anti-diabetic drug 6,809 (25.8)
Any diabetesmedication 19,045 (72.1)
Complications Diabetic nephropathy 20 (0.08)
Age at diabetic nephropathy, years 55 (40–63)
Diabetic neuropathy/ ulcers 153 (0.6)
Age at diabetic neuropathy, years 54 (46–60)
Diabetic eye disease 1,172 (4.4)
Age at diabetic eye disease, years 54 (46–61)
Any diabetes complication 1,293 (4.9)
Data are n (%), n (% women) for gestational diabetes variables or median (IQR).
doi:10.1371/journal.pone.0162388.t002
Recommendations for Diabetes Definition in UK Biobank
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Fig 2. (a) Prevalence algorithm1: Distinctionbetweendiabetes presenceor absence, and initial sortingof diabetes type using baselineUK
Biobankassessmentdata.See S1 appendix for rationale and furtherdata for each step. (b) Prevalence algorithm 2: Finalising type 1 diabetes
diagnosis and classification into probable and possible categories.See S1 appendix for rationale and furtherdata for each step.(c) Prevalence
algorithm 3: Finalising type 2 diabetesdiagnosis and classification into probable and possible categories. See S1 appendix for rationale and
furtherdata for each step.(d) Final diabetesdiagnostic status in UKB.
doi:10.1371/journal.pone.0162388.g002
Recommendations for Diabetes Definition in UK Biobank
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c). UKB baseline self-reportdata vs. secondarycare data in UKB: In our comparison of
prevalent diabetes status by self-report algorithm vs. secondary care data in UKB, we
again found a very low occurrence (0.2%) of diabetes codes in secondary care data for
participants assigned "diabetes unlikely" status fromUKB questionnaire (Table 4).
Of participants assigned "probable” type 1 diabetes, 83% had corroborative hospital admis-
sions, of these, 76% had type 1-specific E10 diabetes diagnostic code. The corresponding
Table 3. Cross-tabulationof final diabetes status from UKBiobankprevalence algorithms against primary care diabetes data for linkedWelsh UK
Biobankparticipants.
Classification of diabetes status of
UKB population according to UKB
data
Diabetes
unlikely
Uncertain
diabetes
status
Gestational
diabetes
Probable type
1 diabetes
Possible type
1 diabetes
Probable type
2 diabetes
Possible type
2 diabetes
Numbers (%),N = 12,228 11560(95) 0 23(0.2) 36(0.3) 9(0.1) 513(4.2) 87(0.7)
Any diagnostic code for diabetes in
primarycare (N)
10 0 2 29 8 386 70
Diagnostic
codes
Definite type 1
diabetes codes (C10E)
0 0 0 22 2 3 15
Any type 1 diabetes
codea
0 0 0 27 3 5 21
Definite type 2
diabetes codes (C10F)
9 0 1 6 2 378 55
Any type 2 diabetes
codeb
9 0 1 7 4 383 58
Other/ non-specific
diabetes codes
3 0 0 20 4 163 43
Gestational codes 0 0 2 0 0 0 1
Any type 1 diabetes
code onlyc
0 0 0 20 2 1 11
Any type 2 diabetes
code onlyd
9 0 0 0 3 379 48
Age at first diagnostic
code,median (IQR)
55 (44–61) 34 (27–39) 30 (23–38) 40 (33–46) 56 (50–60) 50 (43–55)
Medication Insulin 1 0 0 28 4 49 62
Insulin only 0 0 0 20 1 1 15
Metformin 6 0 1 9 4 347 55
Metformin only 3 0 1 1 0 97 2
Insulin andMetformin
only
0 0 0 8 1 1 12
Non-metformin oral
anti-diabetic agent
4 0 0 0 3 260 42
Insulin only or first 0 0 0 28 2 1 24
Other
evidence
 1 x HbA1c6.5%or
glucose11.1 mmol/l
8 0 1 27 6 374 67
5 diabetes process of
care codes
7 0 1 22 6 356 63
Dates of relevant primarycare codes precede the UK Biobank assessment date for each patient.
aCodes classified as Type 1 diabetes (definite), insulin dependent diabetes (probable type 1 diabetes) or juvenile onset diabetes (possible type 1 diabetes).
bCodes classified as Type 2 diabetes (definite), non-insulin dependent diabetes (probable type 2 diabetes) or adult onset diabetes (possible type 2
diabetes).
cType 1 diabetes codes, no type 2 diabetes codes (theremay be other or non-specific codes).
dType 2 diabetes codes but no type 1 diabetes codes (theremay be other or non-specific codes).
doi:10.1371/journal.pone.0162388.t003
Recommendations for Diabetes Definition in UK Biobank
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figures for those with "probable” type 2 diabetes were 44% and 96% respectively. Diabetes type-
specific hospital admission codes were less likely to occur in those with “possible” type 1 (41%)
or “possible” type 2 diabetes (69%) with hospital admissions data.
Implementation. A range of final outcome categories was derived for the UKB baseline
cohort, see above (Fig 1D).
Incidence algorithms
Testing.
a). Choosing the most appropriate primary care codes: From the HES-linkedCPRD
dataset, restricted to the UKB age range at recruitment, out of 1,048,972 people with-
out prevalent diabetes from either primary or secondary care data, 46,766 individuals
had a first diabetes diagnostic Read code after 1st January 2006 (Fig 2A). As data
were drawn from primary care records, all diabetes diagnoses had dates; the ascer-
tainment of these varied by criteria used (Fig 3A).
Of these, 95% had at least one corroborative item, such as a positive blood test, hypoglycaemic
medication (excluding metformin alone), or5 diabetes specific process of care codes in their
primary care record. The majority (45,031, 96%), had a specific C10F diagnostic code, giving
an incidence of type 2 diabetes over the 8 year period of follow up of 4%. An additional 16,636
individuals who did not have diabetes Read codes were identified from hypoglycaemic medica-
tion (excluding those on metformin only), blood tests or process of care codes, inflating the
number of incident cases by 27%. These, along with individuals with a non-C10F diabetes-spe-
cific Read code were classified as incident diabetes of uncertain type. Excluding those with
prevalent diabetes according to the UKB algorithm in the linkedWelsh UKB dataset, 2.3%
(265/11560) had de novo C10F Read codes, i.e. incident type 2 diabetes, during follow up. A
sensitivity analysis of people in receipt of metformin alone (with no other evidence of diabetes)
showed that, of a total of 19,447 individuals in CPRD (from 1st January 2006, of the UKB age
range and without prevalent diabetes) only 856 (4.4%) had no other evidence of incident diabe-
tes in their primary care record (e.g. Read codes, hyperglycaemia or>5 diabetes process of care
codes). Of the 987,305 people in CPRD deemed not to have incident diabetes (Fig 3A), there
will thus be a maximum of 856 false negatives (0.09%).
Table 4. Comparison of final diabetesstatus from prevalence algorithms in UKBiobankversus diabetesdiagnoses in secondarycare data at
baseline.
Diabetes
unlikely
Possible
gestational
diabetes
Probable type 1
diabetes
Possible type 1
diabetes
Probable type 2
diabetes
Possible type 2
diabetes
UK Biobank cohort (n = 502,665) 476,191 794 1,487 350 20,570 3,273
Hospital admissions codes present prior to
baseline assessment date (% of all those in
UKB)
284,780 (60) 539 (68) 1,163 (78) 289 (83) 14,659 (71) 2,606 (80)
Diabetes diagnosis in hospital admissions
data at baseline in any position:
Any(% of all hospital data at baseline) 642 (0.2) 13 (2) 963 (83) 242 (84) 6,430 (44) 1,866 (72)
Type 1(% of diabetes diagnoses) 39 (6) 1 (8) 734 (76) 98 (41) 115 (2) 508 (27)
Type 2 (% of diabetes diagnoses) 507 (80) 10 (77) 128 (14) 119 (49) 6,146 (96) 1,292 (69)
Non-specific (% of diabetes diagnoses) 120 (19) 2 (15) 100 (10) 23 (10) 491 (8) 175 (9)
Data are n (%). Derived from hospital admissions (available from 1997 onwards), date of first diabetes code used.
doi:10.1371/journal.pone.0162388.t004
Recommendations for Diabetes Definition in UK Biobank
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b). Choosing the most appropriate number of secondarycare codes:Of the 1,048,972
individuals in CPRDwith no evidence of diabetes prior to January 2006, 25,959 had
diabetes in positions 1–20, and 8,233 in positions 1–2 in their HES records after Janu-
ary 2006. Diabetes was identified in the primary care record, on the basis of a C10 code,
in 74% (19,143) and 77% (6,373) of these individuals respectively. Since these propor-
tions were similar, we performed the remainder of our comparison including all posi-
tions in the individual secondary care record. Using this definition, 2.5% (25,959) of
the CPRD population had incident diabetes, according to secondary care records, over
the follow-up period.Of the 25,959 total, 9% were initially diagnosed in 2006, 10% in
2007, 11% in 2008, 12% in 2009, 13% in 2010, and 14% in subsequent years to 2014.
c). Primary vs. secondarycare data in CPRD:Of the 45,031 individuals in CPRD with
incident diabetes in primary care, 18,440 (41%), had an incident code for diabetes in
secondary care (Table 5). Compared to those with no secondary care code, those
admitted with diabetes were older, more likely to be on medication, and more likely
to suffer from co-morbidities. In contrast, of the 1,003,941 with no diabetes primary
care Read code, 7,519 (0.007%) had secondary care evidence of diabetes. Unsurpris-
ingly, these individuals had weak evidence of diabetes in their primary care record,
such as medication use and hyperglycaemia on blood testing. They were also less
likely to have microvascular, but not macrovascular complications. Thus using sec-
ondary care data alone, it is evident that 29% of incident cases appear to have little
Fig 3. a. Diabetes incidencealgorithms for primary care data, run in CPRD. b. Diabetes incidence algorithm for secondarycare data, run in UK
Biobank-held in-patient data. *Includes categories:probable type 1 diabetes, probable type 2 diabetes,. **ICD-10: E10, E11, E13, E14. Includesmain or
secondarydiagnostic codes for in-patient data.
doi:10.1371/journal.pone.0162388.g003
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corroborative evidence of diabetes in primary care. Combining incident diabetes
from secondary care with those detected in primary care would increase the inci-
dence over the 8 year period of follow up from 4% to 5% in CPRD.
d). Secondarycare data in UKB:Using hospital admissions data linked to UKB identi-
fied 1,627 incident cases of diabetes (Fig 2B), equating to around 0.3% incidence
since inception (2006–2010 to end of 2012 with complete data to end 2010), about
20% of that anticipated from CPRD data using the same definition. All cases had
event dates specified in hospital records for this run of the algorithm, though in
future instances if event dates are not present, cases will not be classed as incident,
since it will not be possible to distinguish between incident and prevalent cases. Most
(85%) cases were categorised as type 2 diabetes.
Implementation. It is envisaged that algorithms determining incidence diabetes will be
applied to the UKB cohort on a yearly basis, once appropriate primary care data become avail-
able (Fig 4).
Table 5. Characteristics of thosewith incident diabetes from 1st January 2006 to 1st January 2015, comparing those identified in primary care
(with or withoutsecondarycare diagnosis) and those identified in secondarycare alone in the CPRD database.
Denominator = 1,048,972 free from
diabetes in CPRD on Jan 1st 2006
Incident Type 2 diabetes diagnostic code (C10F) in primary
care data (from Fig 3A) (n = 45,031)
No incident diabetes diagnostic code
(C10F) in primary care data
(n = 1,003,941)
Incident Secondary care
diabetes diagnostic code*
No secondary care diabetes
diagnostic code at any time
Incident secondarycare diabetes
diagnostic code
n 18,440 26,591 7,519
Age, years 57 (8) 55 (8) 56 (8)
Male sex 10,795 (59) 15,796 (59) 4,318 (57)
Insulin 2,334 (13) 1,072 (4) 409 (5)
Metformin 13,908 (75) 17,613 (66) 496 (7)
Other oral anti-diabetic agent 7,437 (40) 6,675 (25) 253 (3)
Any diabetesmedication 14,750 (80) 18,055 (68) 898 (12)
 1 HbA1c 6.5% (48mmol/mol) or 1
blood glucose 11.1mmol/l
16,510 (90) 23,191 (88) 994 (22)
5 process of care codes 10,799 (59) 12,394 (47) 249 (3)
Diabetes complications:
• Retinopathy 3,697 (20) 3,951 (15) 170 (2)
• Neuropathy 1,249 (7) 982 (4) 177 (2)
• Nephropathy (CKD Stages 3–5 coded) 229 (1) 88 (0.3) 105 (1.4)
BMI, kg/m2 32 (6) 32 (6) 30 (6)
Systolic blood pressure,mmHg 142 (19) 142 (19) 138 (19)
Onmedication for blood pressure 14,812 (80) 19,119 (72) 4,020 (53)
On statins 15,639 (85) 20,980 (79) 3,103 (41)
Co-morbidities:
•Coronary heart disease 3,725 (20) 2,855 (11) 1,190 (16)
•Stroke 139 (1) 81 (0.3) 36 (0.5)
•Heart failure 1,019 (6) 683 (3) 298 (4)
•COPD/ asthma 4,723 (26) 4,981 (19) 1,713 (23)
Data are mean±SDor n (%), extracted from primarycare records on/ as close as possible after 1st January 2006.
*Co-morbidities and diabetic complications are at any time.
doi:10.1371/journal.pone.0162388.t005
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Fig 4. Flow of participantsidentifiedwith diabetes in UKBiobank.*or mid-point of last consultation/episode without diabetes diagnosis (UK
Biobank inception if not available) and 1st diabetes diagnosis dates.
doi:10.1371/journal.pone.0162388.g004
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Each time the algorithms are run, the previous years’ incident cases will move to the pool of
prevalent cases, with the date of onset being provided by the algorithm in parallel with the diag-
nosis. Incidence algorithms will be applied to those with a “diabetes unlikely”, “possible type 1
diabetes”, “possible type 2 diabetes” and “gestational diabetes” alike, since the latter three states
still constitute clinical uncertainty. Therefore event dates for diabetes diagnoses will be calcu-
lated (see “incidence algorithms; derivation” section above for method) using the point where
diabetes is positively confirmed. This algorithm will focus on incident type 2 diabetes; given
the age range of the UKB cohort at baseline (37–73 years), incident diagnoses of gestational or
type 1 diabetes will be rare.
Discussion
We have described the development and testing of algorithms to identify prevalent and inci-
dent diabetes case status for participants in the UKB cohort, using self-report, primary and sec-
ondary care data. The algorithms will be implemented at source and their results made
available to researchers on request. Our prevalence algorithm for self-report data makes a clear
distinction on the basis of certainty between “probable” and “possible” cases of each type of
diabetes. Probable cases of type 1 and 2 diabetes have strong corroborative data in primary
care. Such corroboration is weaker for possible cases of type 1 and type 2 diabetes. Use of pri-
mary care diagnostic Read codes alone appears valid in ascertaining incident type 2 diabetes.
Using secondary care data, yield of incident diabetes cases is increased 3-fold if any mention of
diabetes in any one of 20 positions is used, versus restriction to the first two positions, without
appreciable loss of validity, when compared to primary care data. A significant proportion of
people with incident diabetes (14%) are detectable in secondary care data alone.
Results of the prevalence algorithms based on self-report data showed proportions of overall
type 1 diabetes (~0.5%) and type 2 diabetes (~5%) in UKB being similar to those reported in
the general population[15]. For those designated as “diabetes unlikely”, virtually no partici-
pants had diabetes codes in primary (0.001%) or secondary (0.2%) care records. The majority
of those with a “probable” type 1 diabetes diagnosis had a diabetes code in both primary and in
secondary care, though proportions for the more specific type 1 diabetes codes were lower.
Diagnostic confusion and misclassification for type 1 diabetes has been highlighted[8,9].
Whilst proportions with any diabetes code in hospital admissions data were similar in those
with “possible”, as opposed to those with “probable” type 1 diabetes (84% and 83% respec-
tively), a specific type 1 code was only present in 41% of “possible”, versus 76% in those with a
“probable” diagnosis. For type 2 diabetes, while proportions with type 2 diabetes specific
(C10F) Read code in primary care were similarly high in those with a “probable” versus “possi-
ble” diagnosis (74% versus 63%), the latter were younger at diagnosis, and more likely to be on
insulin alone. In support, 27% of those with hospital admission data assigned to “possible” type
2 diabetes had a type 1 diabetes specific ICD code, compared to just 2% of those with “proba-
ble” type 2 diabetes. These findings, of greater use of insulin alone and a greater likelihood of
having type 1 diabetes specific ICD codes, in people assigned “possible” rather than “probable”
diabetes suggests that this category includes a significant proportion of people who have type 1
diabetes (with an older age of onset), and people with latent autoimmune diabetes in adults
(LADA).
For incident diabetes, we derived a primary care algorithm that included only those with a
type 2 diabetes-specificRead code, the majority of whom had at least one additional confirma-
tory piece of evidence frommedication, hyperglycaemia and diabetes specific process of care
codes. This provides reassurance that these individuals have type 2 diabetes. The remainder,
who did not have a specific type 2 diabetes Read code, or who only had other primary care
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evidence of diabetes (e.g. medications), but no diabetes Read code, were classified as “uncer-
tain”. This distinction allows researchers to choose how strict their definition of diabetes
should be; for those who require greater precision, we would recommend adhering to the type
2 diabetes specific Read code diagnosis alone. The CPRD analysis used a previous C10F Read
code to remove prevalent diabetes and yielded incidence rates of diabetes of 4%, whereas analy-
sies in the linkedWelsh UKB dataset, which removed those with prevalent diabetes according
to our UKB algorithm, yielded a lower incidence of 2.3%. This discrepancy is likely due to his-
torical under-coding of diabetes in primary care, missing around 24% of prevalent cases
according to our analysis of the linkedWelsh UKB dataset. With incentives to improve coding
in the last decade, individuals with long-standing diabetes may have been given a recent diag-
nostic Read code, artificially inflating incidence in CPRD. Using the UKB-specific prevalence
algorithm at baseline should deal with potential misclassification of prevalent as incident cases
in UKB.
Using secondary care admission data, we show that diabetes is not the primary or secondary
cause for hospital admission in the majority of cases. A similar proportion of individuals pos-
sessed diabetes-specificC10F codes, regardless of whether the diabetes ICD-10 code on admis-
sion occupied either the first or second coded position versus any mention of diabetes on
admission, supporting our decision to include all those in secondary care with any mention of
diabetes. Of those identified in primary care, just under half had diabetes recorded on hospital
admission data. These individuals were older, more likely to be on insulin, and more likely to
have diabetes complications than those without secondary care evidence of diabetes, as antici-
pated. A proportion of individuals were identifiedwith type 2 diabetes from secondary care
records alone; unsurprisingly these individuals had less evidence of medication, hyperglycae-
mia and microvascular (but not macrovascular) complications in their primary care record
than those identifiedwith the C10F code in primary care. Combining both primary and sec-
ondary care data to identify diabetes, 86% of the total would be identifiable in primary care,
(with secondary care evidence of diabetes in 41% of these), and 14% of the total would be iden-
tified in secondary care alone. Notably, secondary care out-patient data does not carry ICD
codes and cannot be used for capturing cases.
In CPRD, over the 8 year period of follow up from 2006, using primary care as the only
source would yield a diabetes incidence of 4%, secondary care alone 2.5%, and in combination
5%. The limited evidence of diabetes in the primary care records of those identified through
secondary care alone, makes the use of secondary care data alone, or combining those with sec-
ondary care evidence of diabetes alone with those with primary care evidence difficult. In the
absence of primary care data, researchers using secondary care identification of diabetes will
need to recognise that nearly a third have no evidence of diabetes in primary care, and appear
different, in terms of risk factors and microvascular complications, to those identified in pri-
mary care. A similar argument applies to combining those found in secondary care alone with
those found in primary care.
Our analyses of secondary care data in UKB provided a much lower yield of incident cases
than anticipated from our CPRD analysis. We would have anticipated around 8000 incident
cases based on CPRD, whereas only just over a 1600 were found. The follow up for CPRD com-
menced in 2006, while that for UKB spans 2006–2010, due to staggered recruitment. In addi-
tion, while CPRD has linkedHES data to March 2014, that for UKB is linked to only 2012, and
complete only to December 2010. In addition, as stated above, due to historical undercoding of
diabetes in primary care, it is likely that we excluded only 76% of all prevalent cases in CPRD,
thereby inflating incidence in secondary care. We estimated that, allowing for the impact of dif-
ferences in follow up and definition of prevalent diabetes betweenUKB and CPRD datasets,
the number of anticipated incident cases would be reduced by around 75%, i.e. a yield of 2000
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cases, still higher that actually observed in UKB.With a 5.5% response rate, UKB participants are
not representative of the general population, unlike CPRD registrants.While prevalence of type 1
and type 2 diabetes in UKB are as anticipated from population studies, more generally, UKB par-
ticipants are clearly healthier than their general population counterparts, as demonstrated by
their much lower smoking rates. We hypothesise that participation in UKB attracted distinct
groups of individuals, those with established disease on the one hand, and the very healthy on the
other. Thus whilst prevalence of diabetesmay not differ from population estimates, it is only the
pool of healthy participants who can contribute to incidence, accounting for the much lower
rates of incident disease compared to population samples. Our data underline the dangers of
using UKB data to estimate disease burden (prevalence or incidence) and should not be used for
this purpose[10].However, we do not have evidence to suggest that risk factor associations with
diabetes differmarkedly betweenUKB participants and the general population.
Event dates for our incidence algorithms were derived by taking the mid-point between the
last primary care consultation or hospital admission and the date of the first diabetes code.
This method is likely to give an event date closer to the true onset of diabetes than the date of
the first diabetes code alone (though the latter will be made available to researchers), and will
prevent artefacts in time-to-event analyses, e.g. appearance of incident diabetes being associ-
ated with immediate myocardial infarction. However we acknowledge this approach is a com-
promise, and that the true date of onset cannot be established with the available data.
The chief limitation to this work is data quality–others have consistently shown errors in
self-report, and primary and secondary care data recording[4,5,7–9].Whilst the principle aim
of our work was to overcome these inaccuracies, all algorithms were obligatorily data-driven,
with no gold standard for comparison. Another drawback is a potential delay in ascertainment
of incident cases resulting from the algorithm’s exclusion of individuals receivingmetformin
alone, who are likely to be either newly-diagnosedor well-controlled. However, a sensitivity
analysis indicated that, of the 987,305 people in CPRD deemed not to have incident diabetes,
even in the most adverse scenario (where all the people on metformin alone with no other evi-
dence of diabetes genuinely have diabetes), there would be a maximum of 856 (0.09%) false
negatives. Furthermore, we were willing to tolerate these potential false negatives to avoid false
positive classification of people receivingmetformin for pre-diabetes, obesity or polycystic
ovarian syndrome.
We conclude that use of baseline self-report diabetes data is a pragmatic and valid approach
to defining prevalent cases of diabetes, without missing cases known to primary or secondary
care, and appears to rightly distinguish between “probable” and “possible” states. Regarding
incidence, we suggest that restriction to the type 2 diabetes specific Read code (C10F) in pri-
mary care has the greatest precision. Secondary care data captures around half of all cases with
diabetes, with 70% having corroborative evidence of diabetes in their primary care record, in
the form of a specific diagnostic Read code.We would caution against using diabetes-specific
information, in the form of medication or blood tests, in the absence of these Read codes, or
combining individuals identified in secondary care alone with those identified in primary care.
Whilst we make recommendations, it is acknowledged that UKB data will be used to address
multiple questions, with varying levels of precision, and tolerance of false negatives. We have
therefore, where possible, categorised groups with differing levels of diagnostic certainty, allow-
ing investigators themselves to choose which categories to use in their analyses.
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S1 Appendix. Rationale for logical rules in prevalence algorithms used on UK Biobank
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